These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 32163072)
1. Therapeutic strategy of arsenic trioxide in the fight against cancers and other diseases. Wang QQ; Jiang Y; Naranmandura H Metallomics; 2020 Mar; 12(3):326-336. PubMed ID: 32163072 [TBL] [Abstract][Full Text] [Related]
2. Balance between the toxicity and anticancer activity of arsenic trioxide in treatment of acute promyelocytic leukemia. Wang QQ; Hua HY; Naranmandura H; Zhu HH Toxicol Appl Pharmacol; 2020 Dec; 409():115299. PubMed ID: 33091440 [TBL] [Abstract][Full Text] [Related]
3. Pyrrolidine Dithiocarbamate Enhances the Cytotoxic Effect of Arsenic Trioxide on Acute Promyelocytic Leukemia Cells. Yu S; Ge Z; Chen W; Han J Comb Chem High Throughput Screen; 2023; 26(11):2067-2076. PubMed ID: 36694317 [TBL] [Abstract][Full Text] [Related]
4. Biotransformation of arsenic trioxide by AS3MT favors eradication of acute promyelocytic leukemia: revealing the hidden facts. Maimaitiyiming Y; Zhu HH; Yang C; Naranmandura H Drug Metab Rev; 2020 Aug; 52(3):425-437. PubMed ID: 32677488 [TBL] [Abstract][Full Text] [Related]
5. Resource utilization and cost effectiveness of treating acute promyelocytic leukaemia using generic arsenic trioxide. Bankar A; Korula A; Kulkarni UP; Devasia AJ; Na F; Lionel S; Abraham A; Balasubramanian P; Janet NB; Nair SC; S S; Jeyaseelan V; N J; Prasad J; George B; Mathews V Br J Haematol; 2020 Apr; 189(2):269-278. PubMed ID: 31863602 [TBL] [Abstract][Full Text] [Related]
6. Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia. Breccia M; Foà R Expert Rev Hematol; 2019 Feb; 12(2):81-87. PubMed ID: 30572725 [TBL] [Abstract][Full Text] [Related]
7. c-Myc Inhibition Using 10058-F4 Increased the Sensitivity of Acute Promyelocytic Leukemia Cells to Arsenic Trioxide Via Blunting PI3K/NF-κB Axis. Sayyadi M; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Abolghasemi H; Anoushirvani AA; Bashash D Arch Med Res; 2020 Oct; 51(7):636-644. PubMed ID: 32553459 [TBL] [Abstract][Full Text] [Related]
8. Gelling Bodies: Understanding the Mechanisms Underlying Arsenic Trioxide Action. Salomoni P Cancer Discov; 2023 Dec; 13(12):2505-2506. PubMed ID: 38084094 [TBL] [Abstract][Full Text] [Related]
9. Suppression of proteasome induces apoptosis in APL cells and increases chemo-sensitivity to arsenic trioxide: Proposing a perception in APL treatment. Zamani-Moghaddam N; Mousavi FS; Esmaeili S; Yousefi AM; Safaroghli-Azar A; Bashash D Cancer Treat Res Commun; 2021; 26():100284. PubMed ID: 33387871 [TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide in pediatric cancer - a case series and review of literature. Abele M; Müller SL; Schleicher S; Hartmann U; Döring M; Queudeville M; Lang P; Handgretinger R; Ebinger M Pediatr Hematol Oncol; 2021 Aug; 38(5):471-485. PubMed ID: 33635158 [TBL] [Abstract][Full Text] [Related]
11. Arsenic induced epigenetic changes and relevance to treatment of acute promyelocytic leukemia and beyond. Maimaitiyiming Y; Wang QQ; Hsu CH; Naranmandura H Toxicol Appl Pharmacol; 2020 Nov; 406():115212. PubMed ID: 32882258 [TBL] [Abstract][Full Text] [Related]
12. Novel Mechanistic Insights into the Anti-cancer Mode of Arsenic Trioxide. Wahiduzzaman M; Ota A; Hosokawa Y Curr Cancer Drug Targets; 2020; 20(2):115-129. PubMed ID: 31736446 [TBL] [Abstract][Full Text] [Related]
13. Activation of PPARγ intensified the effects of arsenic trioxide in acute promyelocytic leukemia through the suppression of PI3K/Akt pathway: Proposing a novel anticancer effect for pioglitazone. Esmaeili S; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Salari S; Gharehbaghian A; Hamidpour M; Bashash D Int J Biochem Cell Biol; 2020 May; 122():105739. PubMed ID: 32169580 [TBL] [Abstract][Full Text] [Related]
14. Molecular targets of arsenic trioxide in malignant cells. Miller WH Oncologist; 2002; 7 Suppl 1():14-9. PubMed ID: 11961205 [TBL] [Abstract][Full Text] [Related]
15. Poly(ADP-Ribose) Polymerase Inhibitors for Arsenic Trioxide-Resistant Acute Promyelocytic Leukemia: Synergistic In Vitro Antitumor Effects with Hypomethylating Agents or High-Dose Vitamin C. Giansanti M; De Gabrieli A; Prete SP; Ottone T; Divona MD; Karimi T; Ciccarone F; Voso MT; Graziani G; Faraoni I J Pharmacol Exp Ther; 2021 Jun; 377(3):385-397. PubMed ID: 33820831 [TBL] [Abstract][Full Text] [Related]